Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study.

Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J.

Urology. 2013 May;81(5):1052-7. doi: 10.1016/j.urology.2012.12.021. Epub 2013 Feb 15.

PMID:
23419459
2.

Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.

Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin TJ, Pickard RS, Hasan T, Thorpe AC.

Int J Urol. 2014 Feb;21(2):175-8. doi: 10.1111/iju.12205. Epub 2013 Jul 2.

3.

The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.

Chen YC, Kuo HC.

Neurourol Urodyn. 2014 Jan;33(1):129-34. doi: 10.1002/nau.22395. Epub 2013 Mar 12.

PMID:
23494629
4.
5.

Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder.

Lee WC, Wu CC, Chuang YC, Tain YL, Chiang PH.

J Ethnopharmacol. 2016 May 26;184:1-9. doi: 10.1016/j.jep.2015.12.026. Epub 2015 Dec 21.

PMID:
26719284
6.

Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.

Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P.

J Urol. 2005 Sep;174(3):977-82; discussion 982-3.

PMID:
16094018
7.

Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.

Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.

J Urol. 2012 Jun;187(6):2131-9. doi: 10.1016/j.juro.2012.01.125. Epub 2012 Apr 12.

PMID:
22503020
8.

Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC).

Neuhaus J, Schulte-Baukloh H, Stolzenburg JU, Speroni di Fenizio P, Horn LC, Rüffert H, Hartenstein S, Burger M, Schulze M, Schwalenberg T.

World J Urol. 2012 Oct;30(5):693-700. doi: 10.1007/s00345-011-0774-0. Epub 2011 Oct 4.

PMID:
21969132
9.

Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.

Lahdes-Vasama TT, Anttila A, Wahl E, Taskinen S.

Scand J Urol Nephrol. 2011 Dec;45(6):397-400. doi: 10.3109/00365599.2011.590997. Epub 2011 Jul 8.

PMID:
21740110
10.

Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.

Abdel-Meguid TA.

J Urol. 2010 Dec;184(6):2423-8. doi: 10.1016/j.juro.2010.08.028. Epub 2010 Oct 16.

PMID:
20952003
11.
12.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
13.

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, Bard R, Valiquette L, Baverstock R, Carr L, Radomski S.

J Urol. 2011 Jun;185(6):2229-35. doi: 10.1016/j.juro.2011.02.004. Epub 2011 Apr 16.

PMID:
21497851
14.

OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.

Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.

Neurourol Urodyn. 2013 Nov;32(8):1109-15. doi: 10.1002/nau.22376. Epub 2013 Feb 6.

15.

[Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].

Chenet A, Perrouin-Verbe B, Le Normand L, Labat JJ, Brunel P, Lefort M, Mathé JF.

Ann Readapt Med Phys. 2007 Nov;50(8):651-60. Epub 2007 Apr 20. French.

PMID:
17490775
16.

Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.

Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.

Arch Phys Med Rehabil. 2013 Aug;94(8):1473-81. doi: 10.1016/j.apmr.2013.04.011. Epub 2013 Apr 28. Review.

PMID:
23632286
17.

Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.

Giannantoni A, Mearini E, Del Zingaro M, Porena M.

Eur Urol. 2009 Mar;55(3):705-11. doi: 10.1016/j.eururo.2008.08.048. Epub 2008 Sep 2.

PMID:
18814955
18.

Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.

Grise P, Ruffion A, Denys P, Egon G, Chartier Kastler E.

Eur Urol. 2010 Nov;58(5):759-66. doi: 10.1016/j.eururo.2010.06.035. Epub 2010 Jul 3.

PMID:
20674149
19.

Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.

Grosse J, Kramer G, Jakse G.

BJU Int. 2009 Sep;104(5):651-6. doi: 10.1111/j.1464-410X.2009.08466.x. Epub 2009 Mar 5.

20.

Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.

Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E.

Eur Urol. 2007 Dec;52(6):1729-35. Epub 2007 Sep 4.

PMID:
17884281

Supplemental Content

Support Center